Gut peptides in the treatment of diabetes mellitus.

Published

Journal Article (Review)

It has been known for at least one century that agents secreted from the intestine during meal absorption regulates glucose assimilation. Extensive research during the past three decades has identified two gut hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP, also known as gastric inhibitory polypeptide) that are important in postprandial glucose metabolism. Both peptides are incretins; they are secreted during carbohydrate absorption and increase insulin secretion. Since they are potent insulin secretagogues, GIP and GLP-1 have received considerable attention as potential diabetes therapeutics. However, only GLP-1 exerts insulinotropic properties when administered to patients with Type 2 diabetes. Both GLP-1 and GIP are rapidly inactivated in the circulation by the enzyme dipeptidyl peptidase IV (DPP-IV). The application of GLP-1 into clinical practice has been delayed due to the need to develop compounds that overcome this rapid inactivation. Two approaches have been taken to utilise the insulinotropic and glucose-lowering actions of GLP-1 as an antidiabetic agent: the development of DPP-IV-resistant analogues and the inhibition of DPP-IV. This review focuses on the physiology of GLP-1 and GIP and the advances that have been made thus far in developing treatments based on these physiological incretins for Type 2 diabetes.

Full Text

Duke Authors

Cited Authors

  • Vahl, TP; D'Alessio, DA

Published Date

  • March 2004

Published In

Volume / Issue

  • 13 / 3

Start / End Page

  • 177 - 188

PubMed ID

  • 15013938

Pubmed Central ID

  • 15013938

Electronic International Standard Serial Number (EISSN)

  • 1744-7658

International Standard Serial Number (ISSN)

  • 1354-3784

Digital Object Identifier (DOI)

  • 10.1517/13543784.13.3.177

Language

  • eng